TR
Tadimeti Rao
Janssen Research and Development Spring House, Kalypsys Inc, Ciba-Geigy, University of Alberta, Merck Research Laboratories, Andhra University
0000-0001-5332-7304
Employment
-
Janssen Research and Development Spring House Scientific Director & Fellow2009 - Present
-
Kalypsys Inc Director,Pharmacology and Preclinical Development2003 - 2009
-
Merck Research Laboratories Senior Fellow1993 - 2003
Education
-
Ciba-Geigy Post Doctoral Fellow/Visiting Scientist1987 - 1988
-
University of Alberta PhD1983 - 1987
-
Andhra University M.Pharm1980 - 1982
-
Andhra University B.Pharm1975 - 1980
Projects & Funding
Projects & funding information is unavailable.
Publications (101)
- Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors. Save
- Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis. Save
- Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model. Save
- Citrullination only infrequently impacts peptide binding to HLA class II MHC. Save
- Phenotyping drug polypharmacology via eicosanoid profiling of blood. Save
- Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation. Save
- PI3Kγ kinase activity is required for optimal T-cell activation and differentiation. Save
- Heteroaromatic-aminomethyl quinolones: potent and selective iNOS inhibitors. Save
- Identification and SAR of selective inducible nitric oxide synthase (iNOS) dimerization inhibitors. Save
- Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective… Save